(Q36919975)

17 August 2017

1 reference

title

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders (English)

1 reference

17 August 2017

0 references

3

Ayalew Tefferi

1 reference

17 August 2017

Ross L Levine

1

1 reference

17 August 2017

Animesh Pardanani

series ordinal

2

1 reference

17 August 2017

D Gary Gilliland

series ordinal

4

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

17 August 2017

Nature Reviews Cancer

1 reference

17 August 2017

7

1 reference

17 August 2017

673-683

1 reference

17 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2210

17 August 2017

0 references

cites work

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

21 January 2018

1 reference

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

31 March 2020

1 reference

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

31 March 2020

1 reference

Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm

31 March 2020

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

31 March 2020

1 reference

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

31 March 2020

1 reference

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

31 March 2020

1 reference

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

31 March 2020

1 reference

A gain-of-function mutation of JAK2 in myeloproliferative disorders

31 March 2020

1 reference

Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis.

31 March 2020

1 reference

Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.

31 March 2020

1 reference

The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation

31 March 2020

1 reference

MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.

31 March 2020

1 reference

Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera

31 March 2020

1 reference

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

31 March 2020

1 reference

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

31 March 2020

1 reference

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

31 March 2020

1 reference

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

31 March 2020

1 reference

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

31 March 2020

1 reference

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders.

31 March 2020

1 reference

Jak family of kinases in cancer

31 March 2020

1 reference

Activating alleles of JAK3 in acute megakaryoblastic leukemia

31 March 2020

1 reference

Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line

31 March 2020

1 reference

Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation

31 March 2020

1 reference

Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein

31 March 2020

1 reference

SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma

31 March 2020

1 reference

Jak2 is essential for signaling through a variety of cytokine receptors

31 March 2020

1 reference

Regulation of the Jak2 tyrosine kinase by its pseudokinase domain

31 March 2020

1 reference

Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation

31 March 2020

1 reference

Jak2: normal function and role in hematopoietic disorders

31 March 2020

1 reference

Identification of an acquired JAK2 mutation in polycythemia vera

31 March 2020

1 reference

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

31 March 2020

1 reference

Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells

31 March 2020

1 reference

STAT3 is constitutively active in some patients with Polycythemia rubra vera

31 March 2020

1 reference

Expression of Bcl-x in erythroid precursors from patients with polycythemia vera

31 March 2020

1 reference

Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2

31 March 2020

1 reference

Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction

31 March 2020

1 reference

CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2

31 March 2020

1 reference

Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation

31 March 2020

1 reference

The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3

31 March 2020

1 reference

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

31 March 2020

1 reference

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

31 March 2020

1 reference

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

31 March 2020

1 reference

Characterization of murine JAK2V617F-positive myeloproliferative disease

31 March 2020

1 reference

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

31 March 2020

1 reference

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

31 March 2020

1 reference

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

31 March 2020

1 reference

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

31 March 2020

1 reference

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

31 March 2020

1 reference

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

31 March 2020

1 reference

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin

31 March 2020

1 reference

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

31 March 2020

1 reference

Germline gain-of-function mutations in SOS1 cause Noonan syndrome

31 March 2020

1 reference

Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome.

31 March 2020

1 reference

Familial myeloproliferative disease

31 March 2020

1 reference

Lessons from familial myeloproliferative disorders

31 March 2020

1 reference

Germline KRAS mutations cause Noonan syndrome

31 March 2020

1 reference

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

31 March 2020

1 reference

The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera

31 March 2020

1 reference

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders

31 March 2020

1 reference

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

31 March 2020

1 reference

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

31 March 2020

1 reference

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

31 March 2020

1 reference

The diagnostic interface between histology and molecular tests in myeloproliferative disorders

31 March 2020

1 reference

Hematopathologic findings in chronic idiopathic myelofibrosis

31 March 2020

1 reference

Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status

31 March 2020

1 reference

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

31 March 2020

1 reference

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

31 March 2020

1 reference

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.

31 March 2020

1 reference

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

31 March 2020

1 reference

JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.

31 March 2020

1 reference

Allogeneic hematopoietic stem cell transplantation for myelofibrosis

31 March 2020

1 reference

Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis

31 March 2020

1 reference

Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia

31 March 2020

1 reference

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

31 March 2020

1 reference

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

31 March 2020

1 reference

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

31 March 2020

1 reference

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

31 March 2020

1 reference

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.

31 March 2020

1 reference

Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia

31 March 2020

1 reference

Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions

31 March 2020

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

31 March 2020

1 reference

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

31 March 2020

1 reference

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

31 March 2020

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

31 March 2020

1 reference

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

31 March 2020

1 reference

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

31 March 2020

1 reference

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

31 March 2020

1 reference

JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model

31 March 2020

1 reference

Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.

31 March 2020

1 reference

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

31 March 2020

1 reference

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

31 March 2020

1 reference

V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules

31 March 2020

1 reference

Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction

31 March 2020

1 reference

Polycythemia vera: stem-cell and probable clonal origin of the disease

31 March 2020

1 reference

Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

31 March 2020

1 reference

Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2210

1 reference

Dimensions Publication ID

17 August 2017

0 references

1 reference